$1.94
Value $155M
NAGE and NEM stock compared: price, dividend, valuation and results, from SEC filings.
$1.94
Value $155M
$104.53
Value $114B
Niagen Bioscience (NAGE) has a market value of $155M and Newmont (NEM) $114B. Over the last year, with dividends, NAGE moved -72.0% and NEM +21.2%. The P/E is 15.2 for NAGE and 12.3 for NEM. Dividend yield: NAGE none, NEM 0.99%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
NAGE$155M
NEM$114B
NEM is 732 times NAGE
Revenue, 12 months
NAGE$122M
NEM$26.6B
NEM is 218 times NAGE
Net income, 12 months
NAGE$10M
NEM$9.2B
NEM is 902 times NAGE
Operating margin
NAGE3.9%
NEM–
ROIC
NAGE5.6%
NEM22.0%
16.4 points apart
P/E
NAGE15.2
NEM12.3
NAGE is 1.2 times NEM
Dividend yield
NAGE0.0%
NEM1.0%
1.0 points apart
5-year return
NAGE-66.4%
NEM+106.8%
173.2 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
NAGE-66.4%
NEM+106.8%
| Period | NAGEWith dividends | NEMWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | -72.0%Price -72.0% | +21.2%Price +20.0% |
| 3 years since November 17, 2023 | +35.7%+10.7% a yearPrice +35.7% | +204.6%+45.0% a yearPrice +187.6% |
| 5 years since November 17, 2021 | -66.4%-19.6% a yearPrice -66.4% | +106.8%+15.6% a yearPrice +80.4% |
| 10 years since November 18, 2016 | -23.6%-2.7% a yearPrice -23.6% | +309.1%+15.1% a yearPrice +219.8% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
NAGENiagen BioscienceNEMNewmont
| Price | $1.94 | $104.53 |
|---|---|---|
| Market value | $155M | $114B |
| Enterprise value (EV) | $86M | $110B |
| P/E | 15.2 | 12.3 |
| P/E, 5-year median | – | 15.6 |
| P/B | 1.9 | 3.2 |
| EV/EBIT | 18.0 | 7.8 |
| Free cash flow yield | – | 8.9% |
| Revenue, 12 months | $122M | $26.6B |
|---|---|---|
| Net income, 12 months | $10M | $9.2B |
| Free cash flow, 12 months | – | $10.1B |
| Earnings per share, 12 months | $0.12 | $8.60 |
| Revenue growth, year on year | 30.0% | 21.3% |
| Revenue growth a year, past | +16.9%over 5 years | +14.5%over 5 years |
| EPS growth a year, past | – | +12.7%over 5 years |
| Gross margin | 63.9% | 69.2% |
|---|---|---|
| Operating margin | 3.9% | – |
| Net margin | 8.4% | 34.7% |
| ROIC | 5.6% | 22.0% |
| ROE | 13.0% | 26.7% |
| Cash | $70M | $8.8B |
|---|---|---|
| Total debt | $2.1M | $5.1B |
| Net debt / EBITDA | -12.9 | -0.2 |
| Interest cover | – | – |
| Dividend yield | – | 1.0% |
|---|---|---|
| Dividend per share, 12 months | – | $1.03 |
| Dividend growth a year, past | – | – |
| Buyback yield | 0.2% | 2.0% |
| Shareholder yield | 0.2% | 3.0% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Newmont ($114B) is about 732.0 times Niagen Bioscience ($155M), at today's prices.
Since November 18, 2016, NAGE's price moved -23.6% and NEM's +219.8%. With dividends: NAGE -23.6% (-2.7% a year), NEM +309.1% (+15.1% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Niagen Bioscience and 0.99% for Newmont. Over the last twelve months they paid – and $1.03 per share.
At today's price, the P/E is 15.2 for NAGE and 12.3 for NEM. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 8.4% for Niagen Bioscience and 34.7% for Newmont, and the operating margin 3.9% and –. Revenue was $122M and $26.6B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.